Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 8/20 | 0.54 |
| ▸ | SMO | Q99835 | 3/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | APOB | P04114 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794226 | 0.87 | TRPV1 (0.49) | MTTPSMONR3C1TRPV1APOB | |
| SCHEMBL6788033 | 0.83 | SMO (0.67) | MTTPSMONR3C1KDRTRPV1 | |
| SCHEMBL6792811 | 0.80 | TRPV1 (0.48) | MTTPSMONR3C1TRPV1APOB | |
| SCHEMBL6792294 | 0.80 | FFAR2 (0.49) | MTTPSMOKDRTRPV1APOB | |
| SCHEMBL6793187 | 0.79 | PTGS1 (0.49) | MTTPSMOKDRTRPV1APOB | |
| SCHEMBL6804946 | 0.78 | SMO (0.49) | MTTPSMOKDRAPOBALDH1A1 | |
| SCHEMBL6790537 | 0.78 | TRPV1 (0.46) | MTTPSMOTRPV1APOBALDH1A1 | |
| SCHEMBL6790539 | 0.78 | TRPV1 (0.46) | MTTPSMOTRPV1APOBALDH1A1 | |
| SCHEMBL6788368 | 0.78 | SMO (0.61) | MTTPSMONR3C1KDRTRPV1 | |
| SCHEMBL6792071 | 0.78 | TRPV1 (0.78) | MTTPSMOTRPV1APOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929528-B1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER (US) | 2003-07-23 | — | — | EP | claimed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885SMO 2094/4885NR3C1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.